We know from studies that these treatments do reduce mortality considerably, but we were interested in whether they work equally well in Africa, Asia and Latin America.
The launching of these treatments has been quite staggering. At least a million people are now being treated in the South. That's still perhaps only 15 per cent of all people who need treatment, but it's a significant change compared with two or three years ago.